Search

Your search keyword '"Karrenbeld, A"' showing total 21 results
Start Over Author "Karrenbeld, A" Publisher ovid technologies (wolters kluwer health)
21 results on '"Karrenbeld, A"'

2. Diffuse enteritis after colectomy for ulcerative colitis: two case reports and review of the literature

Author

Arend Karrenbeld, Gerard Dijkstra, Jan H. Kleibeuker, Klaas van der Linde, Sietske Corporaal, and Jan H Voskuil

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Perforation (oil well), Gastroenterology, DISEASE, Endoscopy, Gastrointestinal, Enteritis, SMALL-BOWEL INFLAMMATION, Young Adult, Duodenitis, Internal medicine, medicine, Humans, Ileitis, Colitis, Glucocorticoids, Colectomy, ulcerative colitis, Hepatology, business.industry, Middle Aged, medicine.disease, Ulcerative colitis, digestive system diseases, duodenitis, Calcineurin, Child, Preschool, ILEITIS, diffuse ulcerative enteritis, Colitis, Ulcerative, Female, business, Follow-Up Studies
Abstract

Ulcerative colitis (UC) is an inflammatory disease of the colon. Involvement of the small bowel is limited to backwash ileitis or pouch-related conditions. Here, we report two men with UC who presented with small bowel inflammation and even perforation, within 1 month after subtotal colectomy. Endoscopy showed diffuse enteritis. Histology showed marked apoptosis of epithelial cells in both cases. One patient responded to steroids and the other to a calcineurin inhibitor. Both patients had no evidence of Crohn's disease in the small intestine before this event. Several more cases of small intestinal lesions in patients with well-established UC have been reported. The majority typically presented shortly after colectomy and responded well to steroids. The pathogenesis of this enteritis is unknown, but seems to be distinct from Crohn's disease and may be associated with UC and colectomy.

Published
2009
Full Text
View/download PDF

3. Prognostic significance of K- ras and TP53 mutations in the role of adjuvant chemotherapy on survival in patients with dukes C colon cancer

Author

R. M. W. Hofstra, J.Th.M. Plukker, Charles H.C.M. Buys, WA Bleeker, E Verlind, Sibrand Poppema, Jos Hermans, Arend Karrenbeld, and Vanessa M. Hayes

Subjects
Adult, Male, Pathology, medicine.medical_specialty, Colorectal cancer, medicine.medical_treatment, DNA Mutational Analysis, medicine.disease_cause, Proto-Oncogene Proteins p21(ras), Exon, Surgical oncology, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Humans, Codon, Aged, Neoplasm Staging, Chemotherapy, Mutation, business.industry, Gastroenterology, Exons, General Medicine, Middle Aged, medicine.disease, Combined Modality Therapy, Survival Rate, Chemotherapy, Adjuvant, Fluorouracil, Colonic Neoplasms, Cancer research, Female, Tumor Suppressor Protein p53, business, Adjuvant, Follow-Up Studies, medicine.drug
Abstract

PURPOSE: Mutations in K-ras andTP53 genes are common in colorectal cancer. They affect biologic behavior and might influence chemotherapy susceptibility in these tumors. We investigated whether the survival of patients with Dukes C colon cancer treated with adjuvant chemotherapy is influenced by K-ras andTP53 mutations. METHODS: Mutation screening of the hot spots of the K-ras gene and of the evolutionarily conserved regions of theTP53 gene was performed by denaturing gradient gel electrophoresis technique in formalin-fixed paraffin-embedded specimens of 55 consecutive patients with Dukes C colon cancer treated with adjuvant 5-fluorouracil-based chemotherapy. The median follow-up was 47 (range, 32–66) months. RESULTS: Alterations in the mutation hot spots of K-ras were found at codon 12 (n=11) and 13 (n=4) in 15 of the 55 carcinomas (27 percent). No mutation was found at codon 61. Mutations of a probably causative nature in the evolutionarily conserved regions (exons 5–8) of theTP53 gene were found in 24 tumors (44 percent). K-ras andTP53 mutations were found equally in the group with recurrent disease (7/26 (26 percent) and 12/27 (44 percent), respectively) and in the group without recurrences (8/28 (24 percent) and 12/28 (43 percent), respectively). Cancer-specific survival did not differ significantly between patients with K-ras orTP53 or both mutated and nonmutated tumors, respectively (log-rank test: K-ras, P=0.72 andTP53, P=0.77; K-ras andTP53, P=0.8). Also, potentially aggressive K-ras codon 12 and 13 mutations had the same survival as tumors without these mutations (log-rank test;P=0.73). CONCLUSIONS: Patients with K-ras orTP53 or both mutated Dukes C colon tumors have the same survival as nonmutated tumors when treated with adjuvant chemotherapy. These data suggest that mutations in K-ras orTP53 alone are not prognostic indicators in patients with Dukes C colon cancer receiving adjuvant 5-Fluorouracil-based therapy.

Published
2001
Full Text
View/download PDF

6. Functional Characterization of Mutations in the Myosin Vb Gene Associated With Microvillus Inclusion Disease

Author

Szperl, Agata M, primary, Golachowska, Magdalena R, additional, Bruinenberg, Marcel, additional, Prekeris, Rytis, additional, Thunnissen, Andy-Mark WH, additional, Karrenbeld, Arend, additional, Dijkstra, Gerard, additional, Hoekstra, Dick, additional, Mercer, David, additional, Ksiazyk, Janusz, additional, Wijmenga, Cisca, additional, Wapenaar, Martin C, additional, Rings, Edmond HHM, additional, and van IJzendoorn, Sven CD, additional

Published
2011
Full Text
View/download PDF

9. High-grade dysplasia in sporadic fundic gland polyps

Author

Jalving, Mathilde, primary, Koornstra, Jan J, additional, G??tz, Jan M, additional, van der Waaij, Laurens A, additional, de Jong, Steven, additional, Zwart, Nynke, additional, Karrenbeld, Arend, additional, and Kleibeuker, Jan H, additional

Published
2003
Full Text
View/download PDF

16. Epithelial cell proliferative activity of Barrettʼs esophagus

Author

Peters, F. T. M., primary, Ganesh, S., additional, Kuipers, E. J., additional, de Jager-Krikken, A., additional, Karrenbeld, A., additional, Harms, G., additional, Sluiter, W. J., additional, Koudstaal, J., additional, Klinkenberg-Knol, E. C., additional, Lamers, C. B. H. W., additional, and Kleibeuker, J. H., additional

Published
1998
Full Text
View/download PDF

17. Clinical relevance of transforming growth factor ?, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors

Author

De Jong, Koert P., primary, Stellema, Rudi, additional, Karrenbeld, Arend, additional, Koudstaal, Jan, additional, Gouw, Annette S., additional, Sluiter, Wim J., additional, Peeters, Paul M. J. G., additional, Slooff, Maarten J. H., additional, and De Vries, Elisabeth G. E., additional

Published
1998
Full Text
View/download PDF

18. Colonic epithellal cell proliferation throughout the colon is not affected by supplementary calcium or resistant starch in adenoma patients

Author

B. A. P. Van Gorkom, Jan H. Kleibeuker, Arend Karrenbeld, E.G.E. de Vries, and R. van der Meer

Subjects
medicine.medical_specialty, food.ingredient, Hepatology, Adenoma, Cell growth, business.industry, Gastroenterology, chemistry.chemical_element, Calcium, medicine.disease, food, chemistry, Internal medicine, medicine, Resistant starch, business
Published
1999
Full Text
View/download PDF

20. High frequency of hMSH6 mutations in patients with MSI-low tumors

Author

A. G.J. van der Zee, Arend Karrenbeld, Rolf H. Sijmons, C. H.C.M. Buys, Yue-Zhong Wu, Harmen Hollema, Jan H. Kleibeuker, Mjw Berends, and Robert M.W. Hofstra

Subjects
Oncology, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Gastroenterology, Medicine, In patient, business
Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results